Xenetic Biosciences First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Xenetic Biosciences (NASDAQ:XBIO) First Quarter 2025 Results

Key Financial Results

• Revenue: US$593.3k (up 16% from 1Q 2024).
• Net loss: US$903.1k (loss narrowed by 24% from 1Q 2024).
• US$0.59 loss per share (improved from US$0.78 loss in 1Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Xenetic Biosciences EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 13%. Earnings per share (EPS) exceeded analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 1.6% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 4 warning signs for Xenetic Biosciences (of which 2 are concerning!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.